Regulatory Focus™ > News Articles > 2020 > 3 > COVID-19 therapeutics tracker

COVID-19 therapeutics tracker

Posted 14 May 2021 | By Jeff Craven 

COVID-19 therapeutics tracker

More than a year into the pandemic, only a handful of repurposed therapeutics have been approved to treat COVID-19: dexamethasone in the UK and Japan; Avigan (favilavir) in China, Italy and Russia; and Veklury (remdesivir) in the US, UK and Japan.
 
The US Food and Drug Administration (FDA) has issued emergency use authorizations (EUAs) for a handful of treatments including Eli Lilly and Company’s monoclonal antibodies bamlanivimab with etesevimab as well as Regeneron’s casirivimab and imdevimab. FDA revoked its EUA for bamlanivimab alone on 16 April. Lilly requested the revocation "due to the evolving variant landscape in the U.S. and the full availability of bamlanivimab and etesevimab together," according to a statement. The agency also authorized the use of convalescent plasma and the combination of Gilead’s Veklury and Eli Lilly’s Olumiant (baracitinib). The South Korea Ministry of Food and Drug Safety has authorized Regkirona (regdanvimab), a human monoclonal antibody.
 
Several large international trials are underway. The largest, SOLIDARITY, is led by the World Health Organization (WHO). More than 100 countries have joined SOLIDARITY to evaluate high-profile treatment candidates for COVID-19.

This tracker will be updated weekly with the latest in developments for treatment candidates who have advanced to at least Phase 1 study. If you notice an issue with this data or wish to submit an update, please email Regulatory Focus at news@raps.org.
 
Updated 14 May to include new information on Olumiant, TXA127, casirivimab/imdevimab, VIR-7832, VIR-7831 and heparin.

 

 

 

© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe